Neurocrine Biosciences' performance in 2023 demonstrates a successful strategy focused on growing its core product sales while investing in research and development for future growth. The company's ability to increase net product sales amidst a competitive market is a testament to the strength of its commercial initiatives and the clinical value of INGREZZA.